SK116294A3 - Recombinant human hiv-antibodies, cassette for expression, host cell and pharmaceutical agent against hiv - Google Patents

Recombinant human hiv-antibodies, cassette for expression, host cell and pharmaceutical agent against hiv Download PDF

Info

Publication number
SK116294A3
SK116294A3 SK1162-94A SK116294A SK116294A3 SK 116294 A3 SK116294 A3 SK 116294A3 SK 116294 A SK116294 A SK 116294A SK 116294 A3 SK116294 A3 SK 116294A3
Authority
SK
Slovakia
Prior art keywords
hiv
antibody
chain
neutralizing
recombinant human
Prior art date
Application number
SK1162-94A
Other languages
English (en)
Slovak (sk)
Inventor
Emilio A Emini
Anthony J Conley
George E Mark
L Johnson
David S Pfarr
Original Assignee
Merck & Co Inc
Med Immune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc, Med Immune Inc filed Critical Merck & Co Inc
Publication of SK116294A3 publication Critical patent/SK116294A3/sk

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036Retroviridae, e.g. leukemia viruses
    • C07K16/1045Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SK1162-94A 1992-04-01 1993-03-23 Recombinant human hiv-antibodies, cassette for expression, host cell and pharmaceutical agent against hiv SK116294A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86170192A 1992-04-01 1992-04-01
PCT/US1993/002629 WO1993019785A1 (en) 1992-04-01 1993-03-23 Recombinant human hiv-neutralizing monoclonal antibodies for prevention and treatment of hiv infection

Publications (1)

Publication Number Publication Date
SK116294A3 true SK116294A3 (en) 1996-11-06

Family

ID=25336532

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1162-94A SK116294A3 (en) 1992-04-01 1993-03-23 Recombinant human hiv-antibodies, cassette for expression, host cell and pharmaceutical agent against hiv

Country Status (19)

Country Link
EP (1) EP0577243A3 (fi)
JP (1) JPH06217791A (fi)
KR (1) KR950700761A (fi)
CN (1) CN1081716A (fi)
AU (2) AU3928593A (fi)
BG (1) BG99074A (fi)
CA (1) CA2093099A1 (fi)
CZ (1) CZ239694A3 (fi)
FI (1) FI944561A (fi)
HU (1) HUT70461A (fi)
IL (1) IL105145A0 (fi)
MX (1) MX9301858A (fi)
NO (1) NO943653L (fi)
NZ (1) NZ251582A (fi)
RU (1) RU94045907A (fi)
SK (1) SK116294A3 (fi)
WO (1) WO1993019785A1 (fi)
YU (1) YU22693A (fi)
ZA (1) ZA932308B (fi)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1277762B1 (en) * 1998-10-30 2008-03-26 Novozymes A/S Low allergenic protein variants
RU2221873C2 (ru) * 2001-04-24 2004-01-20 Закрытое акционерное общество "АСГЛ-Фармацевтические Инновации" Способ получения каталитических антител (варианты), антигены для иммунизации и нуклеотидная последовательность
US7560529B2 (en) 2001-04-24 2009-07-14 FDS Pharma Method for producing catalytic antibodies (variants), antigens for immunization and nucleotide sequence
FR2844455B1 (fr) * 2002-09-13 2007-12-14 Lab Francais Du Fractionnement Traitement des pathologies echappant a la reponse immune par des anticorps optimises
ES2528738T3 (es) 2003-02-20 2015-02-12 The Chemo-Sero-Therapeutic Research Institute Método para potenciar la eficacia de una preparación de un anticuerpo monoclonal
JP2010536885A (ja) * 2007-08-24 2010-12-02 ノバルティス アーゲー V3ループに改変を有するhivenvタンパク質
EA021377B9 (ru) 2008-12-09 2015-09-30 Джилид Сайэнс, Инк. Модуляторы толл-подобных рецепторов
WO2015117008A2 (en) 2014-01-31 2015-08-06 The Rockefeller University Broadly neutralizing anti-hiv antibodies and epitope therefor
TWI806081B (zh) 2014-07-11 2023-06-21 美商基利科學股份有限公司 用於治療HIV之toll樣受體調節劑
UY36298A (es) 2014-09-16 2016-04-29 Gilead Science Inc Formas sólidas de un modulador del receptor tipo toll
WO2021227138A1 (zh) * 2020-05-09 2021-11-18 江苏省疾病预防控制中心(江苏省公共卫生研究院) 针对新型冠状病毒的单克隆抗体或其抗原结合部分

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2520464B2 (ja) * 1987-05-29 1996-07-31 タノツクス・バイオシステムズ・インコーポレーテツド Hiv―1を中和するモノクロ―ナル抗体
EP0311228A3 (en) * 1987-10-09 1990-05-02 Repligen Corporation Recombinant polypeptides and their uses, including assay for aids virus
PT94276A (pt) * 1989-06-05 1991-02-08 Anticorpo monoclonal capaz de neutralizar o prototipo mn de hiv
EP0535154A4 (en) * 1990-06-15 1993-12-01 New York University Heterohybridomas producing human monoclonal antibodies to hiv-1
EP0624193A1 (en) * 1992-01-29 1994-11-17 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Aamp-1, a protein with local homologies to hiv-1 env and nef proteins

Also Published As

Publication number Publication date
AU3563093A (en) 1993-10-07
IL105145A0 (en) 1993-07-08
JPH06217791A (ja) 1994-08-09
NZ251582A (en) 1997-07-27
CA2093099A1 (en) 1993-10-02
HU9402824D0 (en) 1994-11-28
YU22693A (sh) 1997-01-08
AU658987B2 (en) 1995-05-04
EP0577243A3 (en) 1994-11-02
HUT70461A (en) 1995-10-30
AU3928593A (en) 1993-11-08
NO943653D0 (no) 1994-09-30
MX9301858A (es) 1994-03-31
BG99074A (en) 1995-11-30
FI944561A0 (fi) 1994-09-30
FI944561A (fi) 1994-09-30
WO1993019785A1 (en) 1993-10-14
EP0577243A2 (en) 1994-01-05
CZ239694A3 (en) 1995-07-12
ZA932308B (en) 1994-09-30
CN1081716A (zh) 1994-02-09
KR950700761A (ko) 1995-02-20
NO943653L (no) 1994-11-30
RU94045907A (ru) 1996-11-10

Similar Documents

Publication Publication Date Title
US11192941B2 (en) Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof
US20120269821A1 (en) Hiv-1 antibodies
US5665569A (en) HIV immunotherapeutics
AU728748B2 (en) Recombinant human IgA-J. chain dimer
KR100304333B1 (ko) 재조합의사람화된항-사람면역결핍바이러스항체
US20110212106A1 (en) Hiv-1 neutralizing antibodies and uses thereof
Valdez et al. Complementary and synergistic activities of anti-V3, CD4bs and CD4i antibodies derived from a single individual can cover a wide range of HIV-1 strains
SK116294A3 (en) Recombinant human hiv-antibodies, cassette for expression, host cell and pharmaceutical agent against hiv
KR100251823B1 (ko) 사람 면역 결핍 바이러스(hiv) 감염의 면역치료용 모노클로날 항체
EP1373318A2 (en) Neutralizing human monoclonal antibodies against hiv-1, their production and uses
Okamoto et al. In SCID-hu mice, passive transfer of a humanized antibody prevents infection and atrophic change of medulla in human thymic implant due to intravenous inoculation of primary HIV-1 isolate
US20150239961A1 (en) Adcc-mediating antibodies, combinations and uses thereof
MATSUSHITA et al. Characterization of a mouse/human chimeric monoclonal antibody (Cβ1) to a principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein
CA2122044C (en) Hiv immunotherapeutics
RU2134724C1 (ru) Гуманизированное антитело и способ его получения, полинуклеотид (варианты), гибридомная клеточная линия (варианты)
KR100282576B1 (ko) 사람 면역 결핍 바이러스 면역치료제
Major et al. Construction and characterization of chimeric and humanized forms of a broadly neutralizing monoclonal antibody to HIV-1
Ramirez Valdez Identification, isolation and characterization of monoclonal antibodies against HIV-1
AU2002241965A1 (en) Neutralizing human monoclonal antibodies against HIV-1, their production and uses